Neurology

EMA Panel Backs Solriamfetol (Sunosi) for Narcolepsy, OSA

The dual-acting dopamine and norepinephrine reuptake inhibitor showed durable effects in reducing excessive sleepiness in patients with narcolepsy or obstructive sleep apnea (OSA).
International Approvals

Source link




Related posts

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD

Newsemia

Clinical Reasoning: A 58-year-old woman presents with progressive memory deficits, odd behavior, and falls

Newsemia

UF neurosurgery and neurology departments team up for interdisciplinary NIH grant

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy